https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=38421077&retmode=xml&tool=Litmetric&email=readroberts32@gmail.com&api_key=61f08fa0b96a73de8c900d749fcb997acc09 384210772024082320240827
1468-30833892024SepJournal of the European Academy of Dermatology and Venereology : JEADVJ Eur Acad Dermatol VenereolPrevention of amputation by neoadjuvant therapy with pembrolizumab in acrolentiginous melanoma.e820e822e820-e82210.1111/jdv.19920HansenIngaIDepartment of Dermatology and Venereology, University Skin Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.RüngerAlessandraADepartment of Dermatology and Venereology, University Skin Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.NoebelClaraCDepartment of Dermatology and Venereology, University Skin Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.GeidelGlennG0009-0008-3999-5902Department of Dermatology and Venereology, University Skin Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.KöttJulianJ0000-0003-2073-3909Department of Dermatology and Venereology, University Skin Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.MenzAnneAInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.HildebrandtLinaLDepartment of Dermatology and Venereology, University Skin Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.SchneiderStefan WSWDepartment of Dermatology and Venereology, University Skin Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.GebhardtChristofferC0000-0001-7090-9584Department of Dermatology and Venereology, University Skin Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.engLetterCase Reports20240229
EnglandJ Eur Acad Dermatol Venereol92160370926-99590Antibodies, Monoclonal, Humanized0Antineoplastic Agents, ImmunologicalDPT0O3T46PpembrolizumabIMHumansAmputation, SurgicalAntibodies, Monoclonal, Humanizedtherapeutic useAntineoplastic Agents, Immunologicaltherapeutic useMelanomadrug therapysurgeryNeoadjuvant TherapySkin Neoplasmsdrug therapypathology20231029202421520248231245202422912432024229854ppublish3842107710.1111/jdv.19920REFERENCESPatel SP, Othus M, Chen Y, Wright GP Jr, Yost KJ, Hyngstrom JR, et al. Neoadjuvant‐adjuvant or adjuvant‐only pembrolizumab in advanced melanoma. N Engl J Med. 2023;388(9):813–823.Reijers ILM, Menzies AM, van Akkooi ACJ, Versluis JM, van den Heuvel NMJ, Saw RPM, et al. Personalized response‐directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high‐risk stage III melanoma: the PRADO trial. Nat Med. 2022;28(6):1178–1188.Versluis JM, Menzies AM, Sikorska K, Rozeman EA, Saw RPM, van Houdt WJ, et al. Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN‐neo trials. Ann Oncol. 2023;34(4):420–430.Geidel G, Adam L, Runger A, Menz A, Kott J, Haalck T, et al. Neoadjuvant cemiplimab induces durable complete response in locally advanced cutaneous squamous cell carcinoma. J Eur Acad Dermatol Venereol. 2023;37:e1414–e1416.Topalian SL, Bhatia S, Amin A, Kudchadkar RR, Sharfman WH, Lebbe C, et al. Neoadjuvant nivolumab for patients with resectable Merkel cell carcinoma in the CheckMate 358 trial. J Clin Oncol. 2020;38(22):2476–2487.Garbe C, Amaral T, Peris K, Hauschild A, Arenberger P, Basset‐Seguin N, et al. European consensus‐based interdisciplinary guideline for melanoma. Part 2: treatment – update 2022. Eur J Cancer. 2022;170:256–284.Swetter SM, Tsao H, Bichakjian CK, Curiel‐Lewandrowski C, Elder DE, Gershenwald JE, et al. Guidelines of care for the management of primary cutaneous melanoma. J Am Acad Dermatol. 2019;80(1):208–250.Cochran AM, Buchanan PJ, Bueno RA Jr, Neumeister MW. Subungual melanoma: a review of current treatment. Plast Reconstr Surg. 2014;134(2):259–273.Duarte AF, Correia O, Barros AM, Ventura F, Haneke E. Nail melanoma in situ: clinical, dermoscopic, pathologic clues, and steps for minimally invasive treatment. Dermatologic Surg. 2015;41(1):59–68.Garbe C, Dummer R, Amaral T, Amaria RN, Ascierto PA, Burton EM, et al. Neoadjuvant immunotherapy for melanoma is now ready for clinical practice. Nat Med. 2023;29(6):1310–1312.